Caring for the breast cancer survivor’s health and well-being

Figure 2 Adjuvant treatment associated with ovarian suppression/failure with or without concomitant aromatase inhibitor use in women who experience premature menopause[92]. ^aErythrocyte sedimentation rate, full blood count, bone and liver function (calcium phosphate, alkaline phosphatase, albumin, AST/γGT), serum creatinine, endomysial antibodies, serum thyroid stimulating hormone; ^bAlendronate 70 mg per week, risedronate 35 mg per week, ibandronate (150 mg po monthly or 3 mg iv 3-monthly), zoledronic acid 4 mg iv 6-monthly; ^cTo be given as ≥ 1 g of calcium + ≥ 800 IU of vitamin D; ^dBiochemical markers such as serum C-terminal telopeptide of type I collagen or urinary N-telopeptide of type I collagen. Reprinted with permission. © (2008) Elsevier.